JP2018530557A5 - - Google Patents

Download PDF

Info

Publication number
JP2018530557A5
JP2018530557A5 JP2018517362A JP2018517362A JP2018530557A5 JP 2018530557 A5 JP2018530557 A5 JP 2018530557A5 JP 2018517362 A JP2018517362 A JP 2018517362A JP 2018517362 A JP2018517362 A JP 2018517362A JP 2018530557 A5 JP2018530557 A5 JP 2018530557A5
Authority
JP
Japan
Prior art keywords
pyrazolo
pyridine
carboxylic acid
phenyl
cyclobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018517362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530557A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/056028 external-priority patent/WO2017060873A1/en
Publication of JP2018530557A publication Critical patent/JP2018530557A/ja
Publication of JP2018530557A5 publication Critical patent/JP2018530557A5/ja
Pending legal-status Critical Current

Links

JP2018517362A 2015-10-09 2016-10-07 置換ピラゾロ[3,4−b]ピリジン−6−カルボン酸およびこの使用 Pending JP2018530557A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562239475P 2015-10-09 2015-10-09
US62/239,475 2015-10-09
PCT/IB2016/056028 WO2017060873A1 (en) 2015-10-09 2016-10-07 Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use

Publications (2)

Publication Number Publication Date
JP2018530557A JP2018530557A (ja) 2018-10-18
JP2018530557A5 true JP2018530557A5 (enExample) 2019-11-14

Family

ID=57200057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018517362A Pending JP2018530557A (ja) 2015-10-09 2016-10-07 置換ピラゾロ[3,4−b]ピリジン−6−カルボン酸およびこの使用

Country Status (10)

Country Link
US (1) US9796711B2 (enExample)
EP (1) EP3359539A1 (enExample)
JP (1) JP2018530557A (enExample)
CN (1) CN108431002A (enExample)
AU (1) AU2016333855A1 (enExample)
BR (1) BR112018007145A2 (enExample)
CA (1) CA3001094A1 (enExample)
MX (1) MX2018004364A (enExample)
TW (1) TW201735769A (enExample)
WO (1) WO2017060873A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
EP3558982A1 (en) 2016-12-20 2019-10-30 AbbVie S.À.R.L. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
JP7548814B2 (ja) * 2017-09-20 2024-09-10 ハンジョウ イノゲート ファーマ カンパニー リミテッド Ido阻害剤および/またはido-hdac二重阻害剤としての多環式化合物
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020178316A1 (en) * 2019-03-05 2020-09-10 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. 5- or 7-azaindazoles as beta-lactamase inhibitors
GB201905711D0 (en) 2019-04-24 2019-06-05 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
EP3747882A1 (en) 2019-06-03 2020-12-09 AbbVie Overseas S.à r.l. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US11236067B2 (en) 2019-07-12 2022-02-01 Orphomed, Inc. Compound for treating cystic fibrosis
US20220213041A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
WO2022150174A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
KR20240168948A (ko) * 2022-02-08 2024-12-02 이턴 바이오파마 (상하이) 코., 엘티디. 바이사이클릭 헤테로아릴 화합물들 및 이의 용도들

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
EP1765347A4 (en) 2004-06-04 2008-10-01 Univ California COMPOUNDS INVOLVED IN ACCELERATION OF ION TRANSPORT BY MUTANT CFTR AND USES THEREOF
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
RS53895B1 (sr) 2004-06-24 2015-08-31 Vertex Pharmaceuticals Incorporated Modulatori atp-vezujućih kasetnih transportera
US8362031B2 (en) * 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
JP2009529047A (ja) * 2006-03-07 2009-08-13 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環系ピラゾール化合物およびその使用
ES2548292T3 (es) 2007-05-25 2015-10-15 Vertex Pharmaceuticals Incorporated Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP2231280B1 (en) 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
WO2009076593A1 (en) 2007-12-13 2009-06-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MX2011004374A (es) 2008-10-23 2011-05-23 Vertex Pharma Formas solidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluo rometil)fenil)-4-oxo-5-(trifluorometil)-1,4-dihidroquinolin-3-car boxamida.
JP5699090B2 (ja) 2008-12-30 2015-04-08 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012048181A1 (en) 2010-10-08 2012-04-12 N30 Pharmaceuticals, Llc Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
CN103946221B (zh) 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2760463B1 (en) 2011-09-20 2018-11-21 The University of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
CA2891962A1 (en) 2012-11-20 2014-05-03 Discoverybiomed, Inc. Small molecule cftr correctors
CA3122383A1 (en) 2013-05-07 2014-11-13 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis.
US9133210B2 (en) 2013-08-08 2015-09-15 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
WO2015138909A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA2942387A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr actvity
TW202140422A (zh) 2014-10-06 2021-11-01 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
SG11201703391VA (en) 2014-10-31 2017-05-30 Abbvie S À R L Substituted chromanes and method of use
US9567322B2 (en) 2014-10-31 2017-02-14 Abbvie S.Á.R.L. Substituted tetrahydropyrans and method of use

Similar Documents

Publication Publication Date Title
JP2018530557A5 (enExample)
US10988478B1 (en) Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
HRP20210935T1 (hr) Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak
JP2018529743A5 (enExample)
RU2016135637A (ru) 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение
RU2018115722A (ru) N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
RU2484091C2 (ru) Производные изоксазоло-пиридина
JP2017505327A5 (enExample)
JP2013526536A5 (enExample)
JP2015524798A5 (enExample)
JP2018530557A (ja) 置換ピラゾロ[3,4−b]ピリジン−6−カルボン酸およびこの使用
JP2018500376A5 (enExample)
HRP20210177T1 (hr) Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
AR119209A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
RU2018105684A (ru) Замещенные трициклические соединения и способ применения
JP2015522002A5 (enExample)
HRP20190763T1 (hr) Spojevi pirazina za liječenje zaraznih bolesti
RU2020129785A (ru) Фармацевтические производные 6,5-гетеробициклического кольца
JP2015537010A5 (enExample)
JP2018522929A5 (enExample)
HRP20210285T1 (hr) Derivati ((piridin-2-il)-amino)pirido[3,4-d]pirimidina i ((piridazin-3-il)-amino)pirido[3,4-d]pirimidina kao inhibitori cdk4/6 za liječenje npr. reumatoidnog artritisa, arterioskleroze, plućne fibroze, cerebralnog infarkta ili raka
JPWO2022147246A5 (enExample)
AU2019286312B2 (en) New isoxazolyl ether derivatives as GABA A alpha5 PAM
JPWO2022216573A5 (enExample)
JPWO2020072504A5 (enExample)